Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...
CFRA analysts increased their price target on shares of Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) to EUR6.50, up from the previous EUR5.00, while keeping a Buy rating on the stock. Currently trading at $54 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback